检索范围:
排序: 展示方式:
Innate immune responses in RNA viral infection
Qian Xu, Yuting Tang, Gang Huang
《医学前沿(英文)》 2021年 第15卷 第3期 页码 333-346 doi: 10.1007/s11684-020-0776-7
关键词: innate immune viral infection intercellular signaling metabolic changes epigenetic changes
Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU
《农业科学与工程前沿(英文)》 2017年 第4卷 第3期 页码 260-267 doi: 10.15302/J-FASE-2016116
关键词: antiviral blood brain barrier chemokines and cytokines innate immunity rabies virus
《医学前沿(英文)》 2022年 第16卷 第4期 页码 596-609 doi: 10.1007/s11684-021-0868-z
关键词: innate immune checkpoint Siglec10 kidney renal clear cell carcinoma
《医学前沿(英文)》 doi: 10.1007/s11684-023-1016-8
关键词: p53 mutation triple-negative breast cancer decitabine DNMT1 IRF7 innate immune response
免疫细胞在器官移植免疫排斥和免疫耐受中的不同作用 Review
干晓杰, 古鉴, 鞠峥, 吕凌
《工程(英文)》 2022年 第10卷 第3期 页码 44-56 doi: 10.1016/j.eng.2021.03.029
器官移植免疫排斥反应是由多种细胞参与的复杂的免疫应答过程,是决定移植成败和患者生存的关键因素。目前大多数器官移植患者采用免疫抑制剂和生物制剂的组合疗法来控制移植器官的免疫排斥反应,然而免疫抑制剂的使用会降低移植患者免疫系统功能,导致严重的并发症,如慢性感染、恶性肿瘤等。因
此,彻底了解器官移植免疫耐受和免疫排斥的相关机制对于开发更好的治疗方案和改善患者预后至关重要。本文对免疫细胞在器官移植免疫排斥和免疫耐受诱导过程中的作用,以及目前针对移植患者处于临床试验阶段的新型细胞治疗进行概述。
Toll-like receptors in innate immunity and infectious diseases
Min-Hao WU, Ping ZHANG, Xi HUANG,
《医学前沿(英文)》 2010年 第4卷 第4期 页码 385-393 doi: 10.1007/s11684-010-0600-x
关键词: Toll-like receptors innate immunity infectious disease inflammation
Innate and adaptive T cells in influenza disease
null
《医学前沿(英文)》 2018年 第12卷 第1期 页码 34-47 doi: 10.1007/s11684-017-0606-8
Influenza is a major global health problem, causing infections of the respiratory tract, often leading to acute pneumonia, life-threatening complications and even deaths. Over the last seven decades, vaccination strategies have been utilized to protect people from complications of influenza, especially groups at high risk of severe disease. While current vaccination regimens elicit strain-specific antibody responses, they fail to generate cross-protection against seasonal, pandemic and avian viruses. Moreover, vaccines designed to generate influenza-specific T-cell responses are yet to be optimized. During natural infection, viral replication is initially controlled by innate immunity before adaptive immune responses (T cells and antibody-producing B cells) achieve viral clearance and host recovery. Adaptive T and B cells maintain immunological memory and provide protection against subsequent infections with related influenza viruses. Recent studies also shed light on the role of innate T-cells (MAIT cells, gd T cells, and NKT cells) in controlling influenza and linking innate and adaptive immune mechanisms, thus making them attractive targets for vaccination strategies. We summarize the current knowledge on influenza-specific innate MAIT and gd T cells as well as adaptive CD8+ and CD4+ T cells, and discuss how these responses can be harnessed by novel vaccine strategies to elicit cross-protective immunity against different influenza strains and subtypes.
关键词: influenza innate T cells CD4+ and CD8+ T cells vaccination
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
《医学前沿(英文)》 2021年 第15卷 第1期 页码 33-42 doi: 10.1007/s11684-019-0735-3
关键词: cancer immunotherapy immune checkpoint inhibitors immune-related adverse events review
Natural killer cells in liver diseases
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 269-279 doi: 10.1007/s11684-018-0621-4
The liver has been characterized as a frontline lymphoid organ with complex immunological features such as liver immunity and liver tolerance. Liver tolerance plays an important role in liver diseases including acute inflammation, chronic infection, autoimmune disease, and tumors. The liver contains a large proportion of natural killer (NK) cells, which exhibit heterogeneity in phenotypic and functional characteristics. NK cell activation, well known for its role in the immune surveillance against tumor and pathogen-infected cells, depends on the balance between numerous activating and inhibitory signals. In addition to the innate direct “killer” functions, NK cell activity contributes to regulate innate and adaptive immunity (helper or regulator). Under the setting of liver diseases, NK cells are of great importance for stimulating or inhibiting immune responses, leading to either immune activation or immune tolerance. Here, we focus on the relationship between NK cell biology, such as their phenotypic features and functional diversity, and liver diseases.
关键词: natural killer cell phenotype immune activation immune tolerance liver diseases
Tangchun Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 816-819 doi: 10.1007/s11684-020-0823-4
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
null
《医学前沿(英文)》 2014年 第8卷 第1期 页码 1-5 doi: 10.1007/s11684-014-0309-3
Hyperthermia is a condition characterized by increased body temperature as a consequence of failed thermoregulation. Hyperthermia occurs when a body produces or absorbs more heat than it dissipates. Hyperthermia also elicits various effects on the physiology of living cells. For instance, fever-range temperature (39β°C to 40β°C) can modulate the activities of immune cells, including antigen-presenting cells, T cells, and natural killer cells. Heat shock temperature (41β°C to 43β°C) can increase the immunogenicity of tumor cells. Cytotoxic temperature (>43β°C) can create an antigen source to induce an anti-tumor immune response. The immunomodulatory effect of hyperthermia has promoted an interest in hyperthermia-aided immunotherapy, particularly against tumors. Hyperthermia has also been used to treat deep fungal, bacterial, and viral skin infections. We conducted a series of open or controlled trials to treat skin human papillomavirus infection by inducing local hyperthermia. More than half of the patients were significantly cured compared with those in the control trial. A series of challenging clinical cases, such as large lesions in pregnant patients or patients with diabetes mellitus, were also successfully and safely managed using the proposed method. However, further studies should be conducted to clarify the underlying mechanisms and promote the clinical applications of hyperthermia.
SARS-CoV-2 variants, immune escape, and countermeasures
《医学前沿(英文)》 2022年 第16卷 第2期 页码 196-207 doi: 10.1007/s11684-021-0906-x
关键词: SARS-CoV-2 COVID-19 vaccine immune escape breakthrough prevention
Multi-target combinatory strategy to overcome tumor immune escape
《医学前沿(英文)》 2022年 第16卷 第2期 页码 208-215 doi: 10.1007/s11684-022-0922-5
关键词: immune checkpoints multi-target immune escape immune-related adverse events combination therapy
标题 作者 时间 类型 操作
Critical roles of chemokines and cytokines in antiviral innate immune responses during rabies virus infection
Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU
期刊论文
Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient
期刊论文
Decitabine induces -mediated immune responses in p53-mutated triple-negative breast cancer: a clinical
期刊论文
Toll-like receptors in innate immunity and infectious diseases
Min-Hao WU, Ping ZHANG, Xi HUANG,
期刊论文
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
期刊论文
Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
Tangchun Wu
期刊论文
Hyperthermia on skin immune system and its application in the treatment of human papillomavirus-infected
null
期刊论文